CLLS vs PMVP

Key Takeaways

• Both CLLS and PMVP operate in the biotechnology sector, focusing on innovative therapies, but CLLS emphasizes gene-editing for allogeneic CAR-T cells while PMVP targets p53 mutations in oncology.
• CLLS shows stronger recent momentum with a 196% one-year return and positive clinical data from its Cema-Cel trial, contrasting PMVP's 45% one-year gain amid cash preservation.
• CLLS trades at $4.27 with a $440M market cap and $206M cash, while PMVP is at $1.35 with a $74M market cap, highlighting differing scales and valuations.
• Recent developments include CLLS's pivotal trial interim data and PMVP's NEJM publication on rezatapopt, boosting sentiment for both.
• Analyst targets suggest upside: $8 for CLLS (87% potential) versus median $5.50 for PMVP (307% potential from current levels).

Introduction

This stock comparison examines CLLS and PMVP, two clinical-stage biotechs navigating the dynamic healthcare landscape. Both companies target unmet needs in oncology through advanced therapies—gene-edited CAR-T cells for CLLS and p53-targeted small molecules for PMVP. Traders seeking momentum in biotech catalysts and investors eyeing relative performance in small-cap health stocks will find value here. Amid recent market volatility, their contrasting trajectories in clinical progress, cash positions, and price action offer insights into sector positioning and potential trade-offs in risk-reward profiles.

CLLS Overview and Recent Performance

Cellectis S.A. (CLLS) is a clinical-stage biopharmaceutical firm specializing in gene-editing technologies for allogeneic CAR-T cell therapies (chimeric antigen receptor T-cells, engineered immune cells targeting cancer). Its pipeline includes candidates like BALLI-01 for acute lymphoblastic leukemia and ALPHA3 for large B-cell lymphoma. In recent market activity, CLLS shares have surged, posting a 196% one-year return and 10.67% YTD gain as of April 2026, trading around $4.27 within a 52-week range of $1.33-$5.48. Market cap stands at $440M with $206M in cash supporting operations into 2027.

Sentiment has strengthened following Q4 2025 earnings, which reported $10.58M revenue despite an EPS miss, and pivotal interim data from the Cema-Cel trial underscoring its allogeneic CAR-T platform's potential. Analyst reiterations, like Citizens JMP's Market Outperform at $8, reflect optimism around manufacturing capabilities and milestone payments, driving recent price behavior amid broader biotech interest.

PMVP Overview and Recent Performance

PMV Pharmaceuticals (PMVP), a precision oncology company, develops small-molecule therapies reactivating mutant p53 proteins in solid tumors. Its lead candidate, rezatapopt, targets a common mutation across cancers. Shares trade near $1.35, with a $74M market cap, in a 52-week range of $0.81-$1.88. Recent performance includes a 45% one-year gain and 10.80% YTD, though monthly dips reflect sector pressures.

Key influences include full-year 2025 results with an EPS beat in Q4 (-$0.34 vs. -$0.40 expected) and a New England Journal of Medicine publication on rezatapopt's first-in-human data showing selective p53 reactivation. These developments have supported relative stability, with analysts forecasting a median $5.50 target. Cash burn management bolsters its position, though smaller scale amplifies volatility compared to peers.

Trending AI Robots

Tickeron’s Trending AI Robots page curates 25 top-performing AI trading bots from over 351 total bots, selected by advanced algorithms for their suitability in current market conditions like volatility in biotech and semiconductors. These bots employ diverse strategies—trend following, swing trading, long/short pairs—across timeframes from 5 minutes to 60 minutes, trading thousands of tickers in stocks, ETFs, and crypto. Performance stats shine: annualized returns up to 136.62%, win rates from 53% to 87%, profit factors reaching 10.87, and equity growth examples like $48,782 on select agents. Outperforming the S&P 500 (e.g., +13.76% monthly vs. SPY's +2.59%), they offer risk-managed signals for copy trading. Explore these bots to enhance your strategy across varying styles and sectors.

Head-to-Head Comparison

CLLS and PMVP share biotech exposure but diverge in business models: CLLS's gene-editing enables off-the-shelf CAR-T scalability, contrasting PMVP's small-molecule focus on p53 for tumor-agnostic applications. Growth drivers include CLLS's pivotal trial momentum and partnerships versus PMVP's clinical validation in NEJM.

Recent momentum favors CLLS with superior returns and higher revenue ($79.6M ttm), while PMVP trades at a deeper discount to analyst targets. Risk factors: CLLS faces debt (114% debt/equity) and EPS losses; PMVP contends with cash burn in a micro-cap frame. Market sentiment leans positive for both amid oncology advances, but CLLS's larger cap offers relative stability.

Tickeron AI Verdict

Tickeron’s AI currently favors CLLS due to its trend consistency from clinical catalysts, stronger relative performance (196% vs. 45% one-year), and cash runway supporting near-term milestones. While PMVP shows promise in p53 data and higher upside potential, CLLS's momentum and platform validation position it probabilistically ahead in the current biotech environment.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.